NORTH AMERICA ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET FORECAST 2022-2030


TABLE OF CONTENTS

 

1.     RESEARCH SCOPE & METHODOLOGY

1.1. STUDY OBJECTIVES

1.2. SCOPE OF STUDY

1.3. METHODOLOGY

1.4. ASSUMPTIONS & LIMITATIONS

2.     EXECUTIVE SUMMARY

2.1. MARKET SIZE & ESTIMATES

2.2. MARKET OVERVIEW

3.     MARKET DYNAMICS

3.1. PARENT MARKET ANALYSIS

3.2. KEY DRIVERS

3.2.1.   GROWING GERIATRIC POPULATION

3.2.2.   RISING PERVASIVENESS OF ALZHEIMER’S DISEASE

3.2.3.   EMERGING NOVEL DIAGNOSTIC TECHNOLOGIES

3.2.4.   INCREASING PIPELINE DRUGS

3.3. KEY RESTRAINTS

3.3.1.   FAILURE OF THE LATE-STAGE DRUGS

3.3.2.   STRINGENT GOVERNMENT REGULATIONS

3.3.3.   LACK OF THE AVAILABILITY OF SURROGATE MARKERS

4.     KEY ANALYTICS

4.1. TIMELINE OF ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET

4.2. PHASES AND STERNNESS OF ALZHEIMER’S DISEASE

4.3. IMPACT OF COVID-19 ON ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET

4.4. KEY MARKET TRENDS

4.5. PORTER’S FIVE FORCES ANALYSIS

4.5.1.   BUYERS POWER

4.5.2.   SUPPLIERS POWER

4.5.3.   SUBSTITUTION

4.5.4.   NEW ENTRANTS

4.5.5.   INDUSTRY RIVALRY

4.6. KEY BUYING CRITERIA

4.7. SUPPLY CHAIN ANALYSIS

4.8. OPPORTUNITY MATRIX

4.9. VENDOR LANDSCAPE

5.     MARKET BY THERAPEUTICS & DIAGNOSTICS

5.1. THERAPEUTICS

5.1.1.   DRUGS

5.1.1.1.        MARKETED DRUGS

5.1.1.2.        PIPELINE DRUGS

5.1.2.   DISEASE STAGE

5.1.2.1.        LATE-STAGE: SEVERE AD

5.1.2.2.        EARLY/MIDDLE STAGE: MILD TO MODERATE AD

5.1.2.3.        PRODROMAL STAGE

5.1.3.   GENERIC & BRANDED

5.1.3.1.        BRANDED

5.1.3.2.        GENERIC

5.2. DIAGNOSTICS

5.2.1.   LUMBAR PUNCTURE TEST

5.2.2.   POSITRON EMISSION TOMOGRAPHY

5.2.3.   ELECTROENCEPHALOGRAPHY

5.2.4.   MAGNETIC RESONANCE IMAGING

5.2.5.   COMPUTED TOMOGRAPHY

5.2.6.   BLOOD TEST

5.2.7.   OTHER DIAGNOSTICS

6.     GEOGRAPHICAL ANALYSIS

6.1. NORTH AMERICA

6.1.1.   MARKET SIZE & ESTIMATES

6.1.2.   KEY GROWTH ENABLERS

6.1.3.   KEY CHALLENGES

6.1.4.   KEY PLAYERS

6.1.5.   COUNTRY ANALYSIS

6.1.5.1.        UNITED STATES

6.1.5.2.        CANADA

7.     COMPETITIVE LANDSCAPE

7.1. KEY STRATEGIC DEVELOPMENTS

7.1.1.   MERGERS & ACQUISITIONS

7.1.2.   PRODUCT LAUNCHES & DEVELOPMENTS

7.1.3.   PARTNERSHIPS & AGREEMENTS

7.1.4.   BUSINESS EXPANSIONS, ANNOUNCEMENTS, & DIVESTITURES

7.2. COMPANY PROFILES

7.2.1.   ALLERGAN PLC (ACQUIRED BY ABBVIE)

7.2.2.   AMARANTUS BIOSCIENCE HOLDINGS INC

7.2.3.   BAXTER INTERNATIONAL INC

7.2.4.   BIOGEN INC

7.2.5.   COGNOPTIX INC

7.2.6.   EISAI CO LTD

7.2.7.   ELI LILLY & COMPANY

7.2.8.   F HOFFMANN-LA ROCHE

7.2.9.   GE HEALTHCARE

7.2.10.                    JOHNSON & JOHNSON

7.2.11.                    LUPIN LIMITED

7.2.12.                    MERCK & CO INC

7.2.13.                    NOVARTIS AG

7.2.14.                    PFIZER INC

7.2.15.                    SIEMENS HEALTHINEERS AG

7.2.16.                    SUN PHARMACEUTICALS INDUSTRIES LTD

7.2.17.                    TEVA PHARMACEUTICAL INDUSTRIES LIMITED

7.2.18.                    ZYDUS CADILA

 

LIST OF TABLES

TABLE 1: MARKET SNAPSHOT - ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS

TABLE 2: NORTH AMERICA ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, BY THERAPEUTICS & DIAGNOSTICS, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

TABLE 3: NORTH AMERICA ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, BY THERAPEUTICS & DIAGNOSTICS, FORECAST YEARS, 2022-2030 (IN $ MILLION)

TABLE 4: NORTH AMERICA ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY DRUGS, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

TABLE 5: NORTH AMERICA ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY DRUGS, FORECAST YEARS, 2022-2030 (IN $ MILLION)

TABLE 6: NORTH AMERICA ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY DISEASE STAGE, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

TABLE 7: NORTH AMERICA ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY DISEASE STAGE, FORECAST YEARS, 2022-2030 (IN $ MILLION)

TABLE 8: NORTH AMERICA ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY GENERIC & BRANDED, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

TABLE 9: NORTH AMERICA ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY GENERIC & BRANDED, FORECAST YEARS, 2022-2030 (IN $ MILLION)

TABLE 10: NORTH AMERICA ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, BY DIAGNOSTICS, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

TABLE 11: NORTH AMERICA ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, BY DIAGNOSTICS, FORECAST YEARS, 2022-2030 (IN $ MILLION)

TABLE 12: NORTH AMERICA ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, BY COUNTRY, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

TABLE 13: NORTH AMERICA ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, BY COUNTRY, FORECAST YEARS, 2022-2030 (IN $ MILLION)

TABLE 14: LEADING PLAYERS OPERATING IN NORTH AMERICA ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET

TABLE 15: LIST OF MERGERS & ACQUISITIONS

TABLE 16: LIST OF PRODUCT LAUNCHES & DEVELOPMENTS

TABLE 17: LIST OF PARTNERSHIPS & AGREEMENTS

TABLE 18: LIST OF BUSINESS EXPANSIONS, ANNOUNCEMENTS, & DIVESTITURES

 

LIST OF FIGURES

 

FIGURE 1: PIPELINE DRUGS RELATED TO ALZHEIMER’S DISEASE

FIGURE 2: KEY MARKET TRENDS

FIGURE 3: PORTER’S FIVE FORCES ANALYSIS

FIGURE 4: KEY BUYING CRITERIA

FIGURE 5: SUPPLY CHAIN ANALYSIS

FIGURE 6: OPPORTUNITY MATRIX

FIGURE 7: VENDOR LANDSCAPE

FIGURE 8: NORTH AMERICA ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, GROWTH POTENTIAL, BY THERAPEUTICS & DIAGNOSTICS, IN 2021

FIGURE 9: NORTH AMERICA ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, BY THERAPEUTICS, 2022-2030 (IN $ MILLION)

FIGURE 10: NORTH AMERICA ALZHEIMER’S DISEASE THERAPEUTICS MARKET, GROWTH POTENTIAL, BY DRUGS, IN 2021

FIGURE 11: NORTH AMERICA ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY MARKETED DRUGS, 2022-2030 (IN $ MILLION)

FIGURE 12: NORTH AMERICA ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY PIPELINE DRUGS, 2022-2030 (IN $ MILLION)

FIGURE 13: NORTH AMERICA ALZHEIMER’S DISEASE THERAPEUTICS MARKET, GROWTH POTENTIAL, BY DISEASE STAGE, IN 2021

FIGURE 14: NORTH AMERICA ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY LATE-STAGE: SEVERE AD, 2022-2030 (IN $ MILLION)

FIGURE 15: NORTH AMERICA ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY EARLY/MIDDLE STAGE: MILD TO MODERATE AD, 2022-2030 (IN $ MILLION)

FIGURE 16: NORTH AMERICA ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY PRODROMAL STAGE, 2022-2030 (IN $ MILLION)

FIGURE 17: NORTH AMERICA ALZHEIMER’S DISEASE THERAPEUTICS MARKET, GROWTH POTENTIAL, BY GENERIC & BRANDED, IN 2021

FIGURE 18: NORTH AMERICA ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY BRANDED, 2022-2030 (IN $ MILLION)

FIGURE 19: NORTH AMERICA ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY GENERIC, 2022-2030 (IN $ MILLION)

FIGURE 20: NORTH AMERICA ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, BY DIAGNOSTICS, 2022-2030 (IN $ MILLION)

FIGURE 21: NORTH AMERICA ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, GROWTH POTENTIAL, BY DIAGNOSTICS, IN 2021

FIGURE 22: NORTH AMERICA ALZHEIMER’S DISEASE DIAGNOSTICS MARKET, BY LUMBAR PUNCTURE TEST, 2022-2030 (IN $ MILLION)

FIGURE 23: NORTH AMERICA ALZHEIMER’S DISEASE DIAGNOSTICS MARKET, BY POSITRON EMISSION TOMOGRAPHY, 2022-2030 (IN $ MILLION)

FIGURE 24: NORTH AMERICA ALZHEIMER’S DISEASE DIAGNOSTICS MARKET, BY ELECTROENCEPHALOGRAPHY, 2022-2030 (IN $ MILLION)

FIGURE 25: NORTH AMERICA ALZHEIMER’S DISEASE DIAGNOSTICS MARKET, BY MAGNETIC RESONANCE IMAGING, 2022-2030 (IN $ MILLION)

FIGURE 26: NORTH AMERICA ALZHEIMER’S DISEASE DIAGNOSTICS MARKET, BY COMPUTED TOMOGRAPHY, 2022-2030 (IN $ MILLION)

FIGURE 27: NORTH AMERICA ALZHEIMER’S DISEASE DIAGNOSTICS MARKET, BY BLOOD TEST, 2022-2030 (IN $ MILLION)

FIGURE 28: NORTH AMERICA ALZHEIMER’S DISEASE DIAGNOSTICS MARKET, BY OTHER DIAGNOSTICS, 2022-2030 (IN $ MILLION)

FIGURE 29: NORTH AMERICA ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, COUNTRY OUTLOOK, 2021 & 2030 (IN %)

FIGURE 30: UNITED STATES ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, 2022-2030 (IN $ MILLION)

FIGURE 31: CANADA ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, 2022-2030 (IN $ MILLION)

 

KEY FINDINGS

 

The North America Alzheimer’s disease therapeutics & diagnostics market is predicted to increase with a 6.46% CAGR between the estimated years 2022 and 2030. Due to anticipated sales growth and the prospect of new therapies gaining market approval, the market is surging in the region.

 

Get more Insights into the North America Alzheimer’s Disease Therapeutics & Diagnostics Market:

https://inkwoodresearch.com/reports/north-america-alzheimers-disease-therapeutics-and-diagnostics-market/

 

MARKET INSIGHTS

The North America Alzheimer’s disease therapeutics & diagnostics market growth evaluation entails the analysis of Canada and United States. According to the Alzheimer Society of Canada, thousands of new cases of dementia are diagnosed every year. By 2031, the number is expected to increase by 66%.

Since currently available drugs are unable to cure the disease, the benefits of these drugs gradually decrease with time. Further private and public insurers limit drug coverage for individuals who meet the insurance conditions. Therefore, the provincial government steps in and is responsible for Canada’s healthcare facilities, which boosts the healthcare industry.

Moreover, advocacy groups like the Alzheimer’s Society of Canada are also trying to improve drug coverage. Thus, owing to all the factors above, the Canadian market for Alzheimer’s disease diagnostics and therapeutics is expected to register healthy growth over the forecast period. 

 

COMPETITIVE INSIGHTS

 

Some of the leading companies in the market include Eli Lilly & Company, Baxter International Inc, Johnson & Johnson, GE Healthcare, etc.

 

Our report offerings include:

·       Explore key findings of the overall market

·       Strategic breakdown of market dynamics (Drivers, Restraints, Opportunities, Challenges)

·       Market forecasts for a minimum of 9 years, along with 3 years of historical data for all segments, sub-segments, and regions

·       Market Segmentation caters to a thorough assessment of key segments with their market estimations

·       Geographical Analysis: Assessments of the mentioned regions and country-level segments with their market share

·       Key analytics: Porter’s Five Forces Analysis, Vendor Landscape, Opportunity Matrix, Key Buying Criteria, etc.

·       Competitive landscape is the theoretical explanation of the key companies based on factors, market share, etc.

·       Company profiling: A detailed company overview, product/services offered, SCOT analysis, and recent strategic developments

 

SEGMENTATION

1.    ALLERGAN PLC (ACQUIRED BY ABBVIE)

2.    AMARANTUS BIOSCIENCE HOLDINGS INC

3.    BAXTER INTERNATIONAL INC

4.    BIOGEN INC

5.    COGNOPTIX INC

6.    EISAI CO LTD

7.    ELI LILLY & COMPANY

8.    F HOFFMANN-LA ROCHE

9.    GE HEALTHCARE

10.          JOHNSON & JOHNSON

11.          LUPIN LIMITED

12.          MERCK & CO INC

13.          NOVARTIS AG

14.          PFIZER INC

15.          SIEMENS HEALTHINEERS AG

16.          SUN PHARMACEUTICALS INDUSTRIES LTD

17.          TEVA PHARMACEUTICAL INDUSTRIES LIMITED

18.          ZYDUS CADILA

 

Comments

Post a Comment

Popular posts from this blog

High Voltage Cable Market: Major End-Users Augment Demands

Image
  High voltage cables (HVCs) are the backbone of electrical infrastructure globally. From their use in commercial and residential infrastructures to industrial end uses in mining, oil & gas factories, power & utilities, etc., HVCs are crucial supplements to the growth of the power sector. Besides, urbanization and industrialization globally are increasing the demand for electric power. Therefore, the surging power demand is expected to result in more power generation and transmission, thereby propelling the requirement for high voltage cables. Inkwood Research predicts that the global high voltage cable market is set to surge with a 5.12% CAGR during the forecast period 2023-2032 .   High Voltage Cable Market: Major End Uses HVCs are extensively utilized for high voltage electric power transmission. Equipped with multiple conductors, structural elements of protective jackets, and insulators, they are designed to transmit electricity efficiently without long-ra...
Read more

UAV Battery Market: Military & Commercial Applications direct Growth

Image
  Unmanned aerial vehicles (UAVs) or automated drones fly for long periods at a controlled speed and height and have a role in many aspects of aviation. They are used in various functions, ranging from food delivery, filming, photography, climate change monitoring, and search operations after natural disasters. With the growing geo-political tension among major countries, UAVs have gained massive demand. This is because drones are used by the military worldwide for surveillance, reconnaissance, and targeted attacks. These devices operate wirelessly, creating a huge requirement for UAV batteries for optimal use. Accordingly, as per our research, the   global UAV battery market   is estimated to generate a whopping   $17.7 billion   in revenue, with a   16.32% CAGR   during the forecast years,   2022-2030 .   UAV Battery: Growing Military Applications Militaries need UAVs for training in combat situations and ISR (intelligence, surveillance, an...
Read more

X-Ray Tube Market: Trending Applications & Novel Developments

Image
 X-ray tube, also known as a Roentgen tube, functions as a specific energy converter that receives electrical energy and converts it into heat (99%) and x-radiation (1%). The primary function of an X-ray tube is to create x-ray photons from electric energy transmitted by the x-ray generator. As per Inkwood Research, the global X-ray tube market is forecasted to rise with a CAGR of 3.81% during the projected years of 2022 to 2030 . Their widespread usage across applications, such as material and structure analysis, CT scanners, X-ray crystallography, and airport luggage scanners, among others, play an essential role in surging the demand and adoption of X-ray tubes worldwide.   X-Ray – An Incredible Contribution to Human Health The discovery of the X-ray in 1895 provided physicians with an effective, non-surgical tool to analyze the inside of the human body. Moreover, following the development of the ‘Coolidge tube’ in 1913, which continues to remain the model that...
Read more